Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration

FASEB J. 2017 Aug;31(8):3425-3438. doi: 10.1096/fj.201601166RR. Epub 2017 Apr 20.

Abstract

Thyroid hormone (TH) signaling regulates cell proliferation, differentiation, and metabolism. Recent studies have implicated TH signaling in cone photoreceptor viability. Using mouse models of retinal degeneration, we demonstrated that antithyroid drug treatment and targeting iodothyronine deiodinases (DIOs) to suppress cellular tri-iodothyronine (T3) production or increase T3 degradation preserves cones. In this work, we investigated the effectiveness of inhibition of the TH receptor (TR). Two genes, THRA and THRB, encode TRs; THRB2 has been associated with cone viability. Using TR antagonists and Thrb2 deletion, we examined the effects of TR inhibition. Systemic and ocular treatment with the TR antagonists NH-3 and 1-850 increased cone density by 30-40% in the Rpe65-/- mouse model of Leber congenital amaurosis and reduced the number of TUNEL+ cells. Cone survival was significantly improved in Rpe65-/- and Cpfl1 (a model of achromatopsia with Pde6c defect) mice with Thrb2 deletion. Ventral cone density in Cpfl1/Thrb2-/- and Rpe65-/- /Thrb2-/- mice was increased by 1- to 4-fold, compared with age-matched controls. Moreover, the expression levels of TR were significantly higher in the cone-degeneration retinas, suggesting locally elevated TR signaling. This work shows that the effects of antithyroid treatment or targeting DIOs were likely mediated by TRs and that suppressing TR protects cones. Our findings support the view that inhibition of TR locally in the retina is a therapeutic strategy for retinal degeneration management.-Ma, H., Yang, F., Butler, M. R., Belcher, J., Redmond, T. M., Placzek, A. T., Scanlan, T. S., Ding, X.-Q. Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.

Keywords: Leber congenital amaurosis; TR antagonist; cone degeneration; cone dystrophy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antithyroid Agents / pharmacology*
  • Antithyroid Agents / therapeutic use
  • Basic-Leucine Zipper Transcription Factors / genetics
  • Basic-Leucine Zipper Transcription Factors / metabolism
  • Cell Death
  • Disease Models, Animal
  • Eye Proteins / genetics
  • Eye Proteins / metabolism
  • Gene Deletion
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / physiology
  • Methimazole / pharmacology*
  • Methimazole / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Phenoxyacetates / pharmacology
  • Receptors, Thyroid Hormone / antagonists & inhibitors*
  • Receptors, Thyroid Hormone / genetics
  • Receptors, Thyroid Hormone / metabolism
  • Retina / metabolism*
  • Retinal Cone Photoreceptor Cells / metabolism
  • Retinal Degeneration / drug therapy*
  • Retinal Degeneration / metabolism
  • Retinal Degeneration / pathology
  • Retinoblastoma
  • Triiodothyronine
  • cis-trans-Isomerases / genetics
  • cis-trans-Isomerases / metabolism

Substances

  • (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid
  • Antithyroid Agents
  • Basic-Leucine Zipper Transcription Factors
  • Eye Proteins
  • Nrl protein, mouse
  • Phenoxyacetates
  • Receptors, Thyroid Hormone
  • Triiodothyronine
  • Methimazole
  • retinoid isomerohydrolase
  • cis-trans-Isomerases